These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3142338)

  • 21. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
    Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP
    Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
    Naber KG; Sörgel F; Kees F; Schumacher H; Metz R; Grobecker H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():199-207. PubMed ID: 2462556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.
    Parent M; St-Laurent M; LeBel M
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1249-53. PubMed ID: 2118328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Sowunmi A; Ifudu ND
    Biol Pharm Bull; 2000 Aug; 23(8):968-72. PubMed ID: 10963305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tissue penetration of ciprofloxacin after single and multiple doses.
    LeBel M; Vallée F; Bergeron MG
    Antimicrob Agents Chemother; 1986 Mar; 29(3):501-5. PubMed ID: 2940974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of fleroxacin in renal impairment.
    Weidekamm E
    Am J Med; 1993 Mar; 94(3A):70S-74S. PubMed ID: 8452185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of rifampin on fleroxacin pharmacokinetics.
    Schrenzel J; Dayer P; Leemann T; Weidekamm E; Portmann R; Lew DP
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2132-8. PubMed ID: 8257135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
    Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB
    Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolism of fleroxacin in man.
    Sörgel F; Seelmann R; Naber K; Metz R; Muth P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():169-78. PubMed ID: 3144535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The metabolism and pharmacokinetics of fleroxacin in healthy subjects.
    Griggs DJ; Wise R; Kirkpatrick B; Ashby JP
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():191-4. PubMed ID: 3144537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
    Hayton WL; Vlahov V; Bacracheva N; Viachki I; Portmann R; Muirhead G; Stoeckel K; Weidekamm E
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2375-80. PubMed ID: 2128442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
    Begg EJ; Robson RA; Saunders DA; Graham GG; Buttimore RC; Neill AM; Town GI
    Br J Clin Pharmacol; 2000 Jan; 49(1):32-8. PubMed ID: 10606835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs.
    Walker RD; Stein GE; Hauptman JG; MacDonald KH; Budsberg SC; Rosser EJ
    Am J Vet Res; 1990 Jun; 51(6):896-900. PubMed ID: 2195927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals.
    Christenson JG; Chan KK; Cleeland R; Dix-Holzknecht B; Farrish HH; Patel IH; Specian A
    Antimicrob Agents Chemother; 1990 Oct; 34(10):1895-900. PubMed ID: 2127171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Ifudu ND; Sowunmi A
    Chemotherapy; 1998; 44(6):369-76. PubMed ID: 9755295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Penetration of ciprofloxacin and fleroxacin into biliary tract.
    Edmiston CE; Suarez EC; Walker AP; Demeure MP; Frantzides CT; Schulte WJ; Wilson SD
    Antimicrob Agents Chemother; 1996 Mar; 40(3):787-91. PubMed ID: 8851613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model.
    Leibovitz E; Keren G; Shabtai M; Barzilai A; Rubinstein E
    J Antimicrob Chemother; 1989 Sep; 24(3):375-85. PubMed ID: 2509411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration.
    Barbhaiya RH; Shukla UA; Gleason CR; Shyu WC; Wilber RB; Pittman KA
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1204-9. PubMed ID: 2393282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Target site concentrations of ciprofloxacin after single intravenous and oral doses.
    Brunner M; Stabeta H; Möller JG; Schrolnberger C; Erovic B; Hollenstein U; Zeitlinger M; Eichler HG; Müller M
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3724-30. PubMed ID: 12435668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new trifluorinated quinolone: Ro 23-6240 (AM 833).
    Weidekamm E; Stöckel K; Dell D
    Drugs Exp Clin Res; 1987; 13(2):85-90. PubMed ID: 3107959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.